hsa-mir-1197: Hsa-mir-1197 is a microRNA that has been studied in various contexts [PMC5710922]. It has been found to have a similar expression profile to RNA-seq findings [PMC5710922] and its expression has been validated in blood samples of patients and healthy controls [PMC5710922]. Differential expression of hsa-mir-1197 has been observed in patients compared to healthy controls [PMC5710922]. Hsa-mir-1197 is one of the hub miRNAs in a ceRNA network and its expression level is lower in patients with lung cancer compared to normal controls [PMC5710922]. It has also been identified as one of the miRNAs downstream of hsa_circ_0006091 [PMC8973770]. Bioinformatics analysis suggests that hsa-mir-1197 may be involved in post-transcriptional regulation and can bind to the 3'-UTR of RIPK1 [PMC7191703]. The rs17548629 C>T variant can affect the binding strength between hsa-mir-1197 and RIPK1 [PMC7191703]. Hsa-mir-1197 has also been found to be associated with inhibiting virus replication, such as SARS-CoV-2 replication [PMC8890551]. It is targeted by other miRNAs, such as hsa-miR-520h, hsa-miR-1298, and hsa-miR 520g [PMC8483823]. Hsa-mir-1197 has also been associated with cancer progression, including bladder cancer, lung cancer, and prostate cancer [PMC8414803]. Overall, hsa-mir-1197 plays a role in various biological processes and its dysregulation may have implications for disease development [PMC8414803].